$EVOK
Evoke Pharma Inc

2019 Q4 Form 10-K Financial Statement

#000156459021012510 Filed on March 11, 2021

View on sec.gov

Income Statement

Concept 2019 Q4 2019 2018 Q4
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $780.0K $3.738M $1.070M
YoY Change -27.1% -4.64% 3.88%
% of Gross Profit
Research & Development $641.5K $3.416M $700.0K
YoY Change -8.35% -16.57% -57.1%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $641.5K $7.154M $1.770M
YoY Change -63.75% -10.73% 8.49%
Operating Profit -$7.154M
YoY Change -10.73%
Interest Expense $10.00K $28.80K $10.00K
YoY Change 0.0% 43.99%
% of Operating Profit
Other Income/Expense, Net $0.00 $28.80K $0.00
YoY Change -93.58% -100.0%
Pretax Income -$1.420M -$7.130M -$1.760M
YoY Change -19.32% -5.81% 467.74%
Income Tax
% Of Pretax Income
Net Earnings -$1.418M -$7.126M -$1.761M
YoY Change -19.45% -5.82% 470.81%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$58.41K -$319.7K -$101.0K
COMMON SHARES
Basic Shares Outstanding 24.23M
Diluted Shares Outstanding

Balance Sheet

Concept 2019 Q4 2019 2018 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $5.660M $5.660M $5.320M
YoY Change 6.39% 6.39% -30.73%
Cash & Equivalents $5.664M $5.660M $5.319M
Short-Term Investments
Other Short-Term Assets $580.0K $330.0K
YoY Change 75.76% 32.0%
Inventory
Prepaid Expenses $581.7K $329.2K
Receivables
Other Receivables
Total Short-Term Assets $6.246M $6.250M $5.648M
YoY Change 10.58% 10.62% -28.78%
LONG-TERM ASSETS
Property, Plant & Equipment $140.0K $140.0K
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $11.55K $10.00K $11.55K
YoY Change 0.0% 0.0% 0.0%
Total Long-Term Assets $150.1K $150.0K $11.55K
YoY Change 1199.36% 1400.0% 0.0%
TOTAL ASSETS
Total Short-Term Assets $6.246M $6.250M $5.648M
Total Long-Term Assets $150.1K $150.0K $11.55K
Total Assets $6.396M $6.400M $5.660M
YoY Change 13.0% 13.07% -28.73%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.030M $1.030M $480.0K
YoY Change 114.58% 114.58% -54.29%
Accrued Expenses $980.0K $980.0K $1.160M
YoY Change -15.52% -15.52% 12.62%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $2.015M $2.020M $1.634M
YoY Change 23.29% 23.93% -21.04%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $0.00
YoY Change -100.0%
Total Long-Term Liabilities $0.00 $0.00
YoY Change -100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $2.015M $2.020M $1.634M
Total Long-Term Liabilities $0.00 $0.00
Total Liabilities $2.015M $2.020M $1.630M
YoY Change 23.62% 23.93% -71.78%
SHAREHOLDERS EQUITY
Retained Earnings -$85.73M -$78.60M
YoY Change 9.07% 10.65%
Common Stock $90.11M $82.63M
YoY Change 9.05% 12.88%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $4.381M $4.380M $4.025M
YoY Change
Total Liabilities & Shareholders Equity $6.396M $6.400M $5.660M
YoY Change 13.0% 13.07% -28.73%

Cashflow Statement

Concept 2019 Q4 2019 2018 Q4
OPERATING ACTIVITIES
Net Income -$1.418M -$7.126M -$1.761M
YoY Change -19.45% -5.82% 470.81%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$1.150M -$5.762M -$1.250M
YoY Change -8.0% -17.43% -54.38%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $6.107M
YoY Change 32.23%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 310.0K 6.107M 0.000
YoY Change 32.23%
NET CHANGE
Cash From Operating Activities -1.150M -5.762M -1.250M
Cash From Investing Activities
Cash From Financing Activities 310.0K 6.107M 0.000
Net Change In Cash -840.0K 344.8K -1.250M
YoY Change -32.8% -114.61% -54.38%
FREE CASH FLOW
Cash From Operating Activities -$1.150M -$5.762M -$1.250M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2020 dei Entity File Number
EntityFileNumber
001-36075
CY2020 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2020 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
20-8447886
CY2020 dei Document Annual Report
DocumentAnnualReport
true
CY2020 dei Document Transition Report
DocumentTransitionReport
false
CY2020 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2020 dei Entity Address Address Line1
EntityAddressAddressLine1
420 Stevens Avenue
CY2020 dei City Area Code
CityAreaCode
858
CY2020 dei Local Phone Number
LocalPhoneNumber
345-1494
CY2020 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 370
CY2020 dei Entity Address City Or Town
EntityAddressCityOrTown
Solana Beach
CY2020 dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2020 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
92075
CY2020 dei Entity Small Business
EntitySmallBusiness
true
CY2020 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2020 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2020Q2 dei Entity Public Float
EntityPublicFloat
88600000
CY2020 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2020 dei Security12b Title
Security12bTitle
Common Stock, par value $0.0001 per share
CY2020 dei Trading Symbol
TradingSymbol
EVOK
CY2020 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-13154671
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
4025320
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
8068939
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
5663833
CY2020Q4 us-gaap Receivables Net Current
ReceivablesNetCurrent
23311
CY2019Q4 us-gaap Receivables Net Current
ReceivablesNetCurrent
CY2020Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
921762
CY2019Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
581706
CY2020Q4 us-gaap Inventory Net
InventoryNet
236480
CY2019Q4 us-gaap Inventory Net
InventoryNet
CY2020Q4 us-gaap Other Assets Current
OtherAssetsCurrent
30300
CY2019Q4 us-gaap Other Assets Current
OtherAssetsCurrent
CY2020Q4 us-gaap Assets Current
AssetsCurrent
9280792
CY2019Q4 us-gaap Assets Current
AssetsCurrent
6245539
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
141705
CY2019Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
138538
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
11551
CY2019Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
11551
CY2020Q4 us-gaap Assets
Assets
9434048
CY2019Q4 us-gaap Assets
Assets
6395628
CY2020Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
1273572
CY2019Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
1033383
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1016232
CY2019Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
843162
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
141705
CY2019Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
138538
CY2020Q4 evok Paycheck Protection Program Loan
PaycheckProtectionProgramLoan
104168
CY2019Q4 evok Paycheck Protection Program Loan
PaycheckProtectionProgramLoan
CY2020Q4 evok Milestone Payable
MilestonePayable
5000000
CY2019Q4 evok Milestone Payable
MilestonePayable
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
7535677
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
2015083
CY2020Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
5000000
CY2019Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
CY2020Q4 us-gaap Accounts Payable And Accrued Liabilities Noncurrent
AccountsPayableAndAccruedLiabilitiesNoncurrent
112994
CY2019Q4 us-gaap Accounts Payable And Accrued Liabilities Noncurrent
AccountsPayableAndAccruedLiabilitiesNoncurrent
CY2020Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
5112994
CY2019Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
CY2020Q4 us-gaap Liabilities
Liabilities
12648671
CY2019Q4 us-gaap Liabilities
Liabilities
2015083
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2019Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2019Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
2662
CY2019Q4 us-gaap Common Stock Value
CommonStockValue
2443
CY2020Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
95667776
CY2019Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
90108492
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-98885061
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-85730390
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
-3214623
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
4380545
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
9434048
CY2019 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
22296089
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
6395628
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2020 us-gaap Share Based Compensation
ShareBasedCompensation
1628558
CY2019 us-gaap Share Based Compensation
ShareBasedCompensation
1373958
CY2020 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
396834
CY2019 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
116676
CY2020 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
236480
CY2019Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2019Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2019Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2019Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
26621954
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
24431914
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
26621954
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
24431914
CY2020 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
23020
CY2020 evok Cost Of Goods Sold Expenses
CostOfGoodsSoldExpenses
86712
CY2020 us-gaap Type Of Cost Good Or Service Extensible List
TypeOfCostGoodOrServiceExtensibleList
us-gaap:ProductMember
CY2019 us-gaap Type Of Cost Good Or Service Extensible List
TypeOfCostGoodOrServiceExtensibleList
us-gaap:ProductMember
CY2020 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
6554825
CY2019 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
3416466
CY2020 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
6428832
CY2019 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
3737987
CY2020 us-gaap Operating Expenses
OperatingExpenses
13070369
CY2019 us-gaap Operating Expenses
OperatingExpenses
7154453
CY2020 us-gaap Operating Income Loss
OperatingIncomeLoss
-13047349
CY2019 us-gaap Operating Income Loss
OperatingIncomeLoss
-7154453
CY2020 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
5672
CY2019 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
28798
CY2020 us-gaap Interest Expense
InterestExpense
112994
CY2020 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.52
CY2019 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.32
CY2020 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
25492169
CY2019 evok Issuance Of Common Stock From At The Market Offerings Value
IssuanceOfCommonStockFromAtTheMarketOfferingsValue
6106922
CY2020 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
119416
CY2020 evok Issuance Of Common Stock From Warrant Exercise Value
IssuanceOfCommonStockFromWarrantExerciseValue
CY2020 evok Issuance Of Common Stock From Stock Option Exercise Value
IssuanceOfCommonStockFromStockOptionExerciseValue
215816
CY2020 evok Issuance Of Common Stock From At The Market Offerings Value
IssuanceOfCommonStockFromAtTheMarketOfferingsValue
3595713
CY2019 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
125150
CY2020 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
73939
CY2019 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
CY2020 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
416426
CY2019 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
106280
CY2020 evok Accrued Interest Expense
AccruedInterestExpense
112994
CY2019 evok Accrued Interest Expense
AccruedInterestExpense
CY2020 evok Milestone Payment
MilestonePayment
5000000
CY2019 evok Milestone Payment
MilestonePayment
CY2020 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-6630007
CY2019 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-5762093
CY2020 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
215816
CY2020 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
3595713
CY2019 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
6106922
CY2020 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
119416
CY2019 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
CY2019 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
CY2020 us-gaap Proceeds From Issuance Of Unsecured Debt
ProceedsFromIssuanceOfUnsecuredDebt
104168
CY2019 us-gaap Proceeds From Issuance Of Unsecured Debt
ProceedsFromIssuanceOfUnsecuredDebt
CY2020 us-gaap Proceeds From Lines Of Credit
ProceedsFromLinesOfCredit
5000000
CY2019 us-gaap Proceeds From Lines Of Credit
ProceedsFromLinesOfCredit
CY2019 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
6106922
CY2019 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
344829
CY2020 us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Use of Estimates </p> <p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States (&#8220;GAAP&#8221;). The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ materially from those estimates. </p>
CY2020 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Concentrations of Risk </p> <p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that potentially subject the Company to significant credit risk consist primarily of cash and cash equivalents. The Company maintains deposits in a federally insured financial institution in excess of federally insured limits. The Company has established guidelines designed to maintain safety and liquidity, has not experienced any losses in such accounts and believes the exposure to significant risk to the cash balance is minimal.</p> <p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company relies on contract research organizations (&#8220;CROs&#8221;) and consultants to assist with ongoing regulatory activities. If the CROs and consultants are unable to continue their support, this could adversely affect the Company&#8217;s operations.</p> <p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, the Company relies on third-party manufacturers for the production of Gimoti. If the third-party manufacturers are unable to continue manufacturing Gimoti, or if the Company loses one of its sole source suppliers used in its manufacturing processes, the Company may not be able to meet any development needs or commercial supply demand for Gimoti, and the development and/or commercialization of Gimoti could be materially and adversely affected. </p> <p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company also relies on a dedicated third-party sales team to sell Gimoti. If such third-party organization is unable to continue serving as a dedicated sales team, the commercialization of Gimoti could be materially and adversely affected.</p>
CY2018Q2 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
6286425
CY2018Q2 evok Share Based Compensation Arrangement By Share Based Payment Award Expiration Month And Year
ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationMonthAndYear
2028-02
us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.75
us-gaap Conversion Of Stock Shares Converted1
ConversionOfStockSharesConverted1
2456999
us-gaap Conversion Of Stock Shares Issued1
ConversionOfStockSharesIssued1
1842746
CY2007Q2 us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
650000
CY2020 us-gaap Common Stock Voting Rights
CommonStockVotingRights
Each share of common stock is entitled to one vote. The holders of the common stock are also entitled to receive dividends whenever funds are legally available and when declared by the board of directors of the Company.
CY2020 us-gaap Dividends Common Stock Cash
DividendsCommonStockCash
0
CY2020Q4 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
871682
CY2020 evok Issuance Of Common Stock From Warrant Exercise Shares
IssuanceOfCommonStockFromWarrantExerciseShares
381625
CY2020Q4 evok Class Of Warrant Or Rights Weighted Average Exercise Price Of Warrants Or Rights Exercisable
ClassOfWarrantOrRightsWeightedAverageExercisePriceOfWarrantsOrRightsExercisable
2.77
CY2020Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
1841879
CY2020 evok Entity Incorporation Month And Year Of Incorporation
EntityIncorporationMonthAndYearOfIncorporation
2007-01
CY2020 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2020Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
0
CY2020 evok Bad Debt Expense
BadDebtExpense
0
CY2020Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
150000
CY2020Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
86000
CY2020 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5931380
CY2019 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5852932
CY2020 evok Lease Commencement Date
LeaseCommencementDate
2017-01-01
CY2020 us-gaap Lease Expiration Date1
LeaseExpirationDate1
2022-01-31
CY2019Q4 evok Operating Lease Right Of Use Estimated Asset
OperatingLeaseRightOfUseEstimatedAsset
139000
CY2019Q1 evok Operating Lease Right Of Use Estimated Asset
OperatingLeaseRightOfUseEstimatedAsset
136000
CY2019Q4 evok Operating Lease Right Of Use Estimated Liability
OperatingLeaseRightOfUseEstimatedLiability
139000
CY2019Q1 evok Operating Lease Right Of Use Estimated Liability
OperatingLeaseRightOfUseEstimatedLiability
136000
CY2020 evok Operating Lease Incremental Borrowing Rate
OperatingLeaseIncrementalBorrowingRate
0.10
CY2020 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
151000
CY2019 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
145000
CY2020Q4 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
137000
CY2020Q4 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
12000
CY2019Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
2713561
CY2020Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
2.98
CY2019Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
0.62
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
84000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
P4Y
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Award Requisite Service Period1
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1
P10Y
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1172000
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
829500
CY2019 us-gaap Stock Issued During Period Shares Employee Stock Purchase Plans
StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
0
CY2020Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
2000000
CY2020 evok Share Based Compensation Arrangements By Share Based Payment Award Options Outstanding Date Intrinsic Value
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOutstandingDateIntrinsicValue
2.58
CY2019 evok Share Based Compensation Arrangements By Share Based Payment Award Options Outstanding Date Intrinsic Value
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOutstandingDateIntrinsicValue
1.62
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.23
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0.91
CY2020Q4 evok Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized For Employee Stock Purchase Plan
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedForEmployeeStockPurchasePlan
244574
CY2018 us-gaap Stock Issued During Period Shares Period Increase Decrease
StockIssuedDuringPeriodSharesPeriodIncreaseDecrease
520000
CY2020Q4 us-gaap Accrued Payroll Taxes Current
AccruedPayrollTaxesCurrent
119000
CY2020 us-gaap Stock Issued During Period Shares Employee Stock Purchase Plans
StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
118491
CY2020 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y1M2D
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4077259
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3114371
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
1402433
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
1587155
CY2019Q4 evok Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized For Employee Stock Purchase Plan
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedForEmployeeStockPurchasePlan
263065
CY2020Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
7566145
CY2019Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
7678152
CY2020 evok Minimum Age Of Employee To Participate In Defined Benefit Plan
MinimumAgeOfEmployeeToParticipateInDefinedBenefitPlan
P21Y
CY2020 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
0
CY2019 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
0
CY2020Q4 us-gaap Income Tax Examination Penalties And Interest Accrued
IncomeTaxExaminationPenaltiesAndInterestAccrued
0
CY2020 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2019 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2020 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
0.06
CY2019 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
0.04
CY2019 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.07
CY2020 evok Effective Income Tax Rate Reconciliation Tax Credits Research And Development
EffectiveIncomeTaxRateReconciliationTaxCreditsResearchAndDevelopment
-0.01
CY2019 evok Effective Income Tax Rate Reconciliation Tax Credits Research And Development
EffectiveIncomeTaxRateReconciliationTaxCreditsResearchAndDevelopment
0.03
CY2020 evok Effective Income Tax Rate Reconciliation Operating Loss And Tax Credits Other
EffectiveIncomeTaxRateReconciliationOperatingLossAndTaxCreditsOther
0.11
CY2019 evok Effective Income Tax Rate Reconciliation Operating Loss And Tax Credits Other
EffectiveIncomeTaxRateReconciliationOperatingLossAndTaxCreditsOther
0.27
CY2020 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
-0.02
CY2019 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
0.04
CY2020 evok Effective Income Tax Rate Reconciliation Deductible Expense Share Based Compensation And Other Permanent Items
EffectiveIncomeTaxRateReconciliationDeductibleExpenseShareBasedCompensationAndOtherPermanentItems
0.01
CY2019 evok Effective Income Tax Rate Reconciliation Deductible Expense Share Based Compensation And Other Permanent Items
EffectiveIncomeTaxRateReconciliationDeductibleExpenseShareBasedCompensationAndOtherPermanentItems
0.04
CY2020Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
20400000
CY2020 evok Cumulative Minimum Change In Ownership Percentage For Limitation On Utilization Of Net Operating Loss Carry Forwards
CumulativeMinimumChangeInOwnershipPercentageForLimitationOnUtilizationOfNetOperatingLossCarryForwards
0.50
CY2020 evok Cumulative Change In Ownership Period
CumulativeChangeInOwnershipPeriod
P3Y
CY2020Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
3500000
CY2020Q4 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
1089000
CY2019Q4 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
80000
CY2020Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
695000
CY2019Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
846000
CY2020Q4 evok Deferred Tax Assets Lease Liability
DeferredTaxAssetsLeaseLiability
59000
CY2019Q4 evok Deferred Tax Assets Lease Liability
DeferredTaxAssetsLeaseLiability
39000
CY2020Q4 evok Deferred Tax Assets Tax Accruals And Other
DeferredTaxAssetsTaxAccrualsAndOther
214000
CY2019Q4 evok Deferred Tax Assets Tax Accruals And Other
DeferredTaxAssetsTaxAccrualsAndOther
237000
CY2020Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
2057000
CY2019Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
1202000
CY2020Q4 evok Deferred Tax Liabilities Right Of Use Asset
DeferredTaxLiabilitiesRightOfUseAsset
59000
CY2019 us-gaap Unrecognized Tax Benefits Period Increase Decrease
UnrecognizedTaxBenefitsPeriodIncreaseDecrease
0
CY2020Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
2000000
CY2019Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
2000000
CY2019Q4 evok Deferred Tax Liabilities Right Of Use Asset
DeferredTaxLiabilitiesRightOfUseAsset
39000
CY2020Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
59000
CY2019Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
39000
CY2020Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
1998000
CY2019Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
1163000
CY2020 evok Percentage Of Taxable Income Offset By Tax Losses
PercentageOfTaxableIncomeOffsetByTaxLosses
0.80
CY2020 us-gaap Unrecognized Tax Benefits Period Increase Decrease
UnrecognizedTaxBenefitsPeriodIncreaseDecrease
0
CY2020Q4 us-gaap Unrecognized Tax Benefits That Would Impact Effective Tax Rate
UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
0

Files In Submission

Name View Source Status
0001564590-21-012510-index-headers.html Edgar Link pending
0001564590-21-012510-index.html Edgar Link pending
0001564590-21-012510.txt Edgar Link pending
0001564590-21-012510-xbrl.zip Edgar Link pending
evok-10k_20201231.htm Edgar Link pending
evok-20201231.xml Edgar Link completed
evok-20201231.xsd Edgar Link pending
evok-20201231_cal.xml Edgar Link unprocessable
evok-20201231_def.xml Edgar Link unprocessable
evok-20201231_lab.xml Edgar Link unprocessable
evok-20201231_pre.xml Edgar Link unprocessable
evok-ex1030_158.htm Edgar Link pending
evok-ex1032_589.htm Edgar Link pending
evok-ex231_7.htm Edgar Link pending
evok-ex311_6.htm Edgar Link pending
evok-ex312_10.htm Edgar Link pending
evok-ex321_9.htm Edgar Link pending
evok-ex322_8.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
gvhlommmgus2000001.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending